BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33168853)

  • 1. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
    Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
    Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
    [No Abstract]   [Full Text] [Related]  

  • 6. Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma.
    Lubin D; Toorens E; Zhang PJ; Jaffer S; Baraban E; Bleiweiss IJ; Nayak A
    Am J Surg Pathol; 2019 Jul; 43(7):1005-1013. PubMed ID: 31094929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
    Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
    J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants.
    LaFramboise WA; Pai RK; Petrosko P; Belsky MA; Dhir A; Howard PG; Becich MJ; Holtzman MP; Ahrendt SA; Pingpank JF; Zeh HJ; Dhir R; Bartlett DL; Choudry HA
    Mod Pathol; 2019 Jul; 32(8):1197-1209. PubMed ID: 30962504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational landscape differences between young-onset and older-onset breast cancer patients.
    Mealey NE; O'Sullivan DE; Pader J; Ruan Y; Wang E; Quan ML; Brenner DR
    BMC Cancer; 2020 Mar; 20(1):212. PubMed ID: 32164620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
    Lopez G; Costanza J; Colleoni M; Fontana L; Ferrero S; Miozzo M; Fusco N
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
    Ye Q; Qi F; Bian L; Zhang SH; Wang T; Jiang ZF
    Chin Med J (Engl); 2017 Mar; 130(5):522-529. PubMed ID: 28229982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study.
    Olivier M; Bouaoun L; Villar S; Robitaille A; Cahais V; Heguy A; Byrnes G; Le Calvez-Kelm F; Torres-Mejía G; Alvarado-Cabrero I; Imani-Razavi FS; Inés Sánchez G; Jaramillo R; Porras C; Rodriguez AC; Garmendia ML; Soto JL; Romieu I; Porter P; Guenthoer J; Rinaldi S;
    PLoS One; 2019; 14(1):e0210372. PubMed ID: 30653559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
    Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
    PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors.
    Thulin A; Andersson C; Werner Rönnerman E; De Lara S; Chamalidou C; Schoenfeld A; Kovács A; Fagman H; Enlund F; Linderholm BK
    Sci Rep; 2021 Dec; 11(1):23548. PubMed ID: 34876602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.
    Yao J; You Q; Zhang X; Zhang Y; Xu J; Zhao X; Li J; Wang X; Gong Z; Zhang D; Wang W
    Clin Genet; 2023 Feb; 103(2):200-208. PubMed ID: 36346122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.